Respectively on June 28, 2018 and June 30, 2018, the National Development and Reform Commission and Ministry of Commerce jointly issued the Special Administration Measures on Foreign Investment Access (Negative List) (2018 Edition) (hereinafter referred to as the “2018 Negative List”) and the Special Administrative Measures on Foreign Investment Access to Pilot Free Trade Zones (Negative List) (2018 Edition) (hereinafter referred to as the “2018 Negative List of FTZ”), to be implemented respectively on July 28, 2018 and July 30, 2018.
On March 9, 2018, the General Office of the National Development and Reform Commission (NDRC) released the Circular on Issues Relating to Strengthen the Monitor of Urban Rail Transit Vehicles Investment Projects ([Fa Gai Ban Chan Ye  No. 323]) (the Circular 323).
To deepen the reform of drug evaluation and approval system, encourage innovations in drugs, and safeguard the rights and interests of the public in regard to drug consumption, China Food and Drug Administration (the “CFDA”) has published series of pharmaceutical laws and regulations recently. Among others, the most notable is the Drug Administration Law of the People’s Republic of China (draft for consultation) (the “Draft”) promulgated on October 23th, 2017 due to several major reforms in the area of drug registration and administration.